Antisense Therapeutics: Raises $5.5M for Phase 2b clinical trial
- Biopharmaceutical company Antisense Therapeutics (ANP) has raised $5.5 million via an options exercise
- The option underwritten by Morgans Corporate, who also acted as the Lead Manager
- Then the funds will used for the Phase 2b clinical trial of the company’s therapy for Duchenne Muscular Dystrophy
- The disease affects one in every 3500 to 6000 male births and characterised by the ongoing deterioration of muscles
- CEO Mark Diamond welcomed the funds and the contribution to the next clinical trial for ATL1102
- Then the shares in Antisense Therapeutics are trading 3.37 per cent lower, worth 8.6 cents apiece
